

NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

99114080	<i>Haloperidol</i>		1 Caps	0.5 mg			
99114081	<i>Haloperidol</i>		1 Caps	1 mg			
99114082	<i>Haloperidol</i>		1 Caps	2 mg			
99114083	<i>Haloperidol</i>		1 Caps	5 mg			
99114084	<i>Haloperidol</i>		1 Caps	2,5 mg			
99114085	<i>Haloperidol</i>		1 Caps	10 mg			

until the following medication, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, is no longer out of stock:

00363685	<i>Teva-Haloperidol</i>	Teva Can	100	0.5 mg	Tab.	13.62	0.1362
00363677	<i>Teva-Haloperidol</i>	Teva Can	100	1 mg	Tab.	20.46	0.2046
00363669	<i>Teva-Haloperidol</i>	Teva Can	100	2 mg	Tab.	30.58	0.3058
00363650	<i>Teva-Haloperidol</i>	Teva Can	100	5 mg	Tab.	4877	0.4877
00713449	<i>Teva-Haloperidol</i>	Teva Can	100	10 mg	Tab.	70.95	0.7095

This notice has effect retroactively from 14 October 2022.

Québec, 25 October 2022

[original signed by]

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.